04.01.2016 • News

Evonik Builds Specialty Copolyester Plant in Germany

Evonik executive board member and chief operating officer Ralf Sven Kaufmann...
Evonik executive board member and chief operating officer Ralf Sven Kaufmann said the company continues to expand its polyester platform and strengthen its position in the metal coatings market, which is growing at an attractive rate.

Evonik has announced plans to build a new specialty copolyester production plant at its site in Witten, Germany.  The company said the investment in the facility s scheduled for completion in 2018 is in the “mid-double digit” million euro range. The plant’s actual capacity figures were not disclosed although Evonik said it would produce “several thousand” tonnes per year.  Ten new jobs will be created at the site which currently employs around 250 people.

Evonik executive board member and chief operating officer Ralf Sven Kaufmann said the company continues to expand its polyester platform and strengthen its position in the metal coatings market, which is growing at an attractive rate.

Specialty copolyesters are the main component in coatings. They are being used increasingly for food can coatings where they provide good sterilization resistance, adequate rigidity and protection. A major driver is the trend toward epoxy resin-free can coatings that do not contain bisphenol A.

Innovation Pitch

The Start-up Platform for Chemistry & Life Sciences
Discover Tomorrow’s Innovators

The Start-up Platform for Chemistry & Life Sciences

CHEManager Innovation Pitch supports innovation in the chemistry and life sciences start-up scene. The platform allows founders, young entrepreneurs, and start-ups to present their companies to the industry.

Expert Insights

ADCs for Precision Cancer Therapy
Comprehensive Insights into Antibody–Drug Conjugates

ADCs for Precision Cancer Therapy

Explore how antibody-drug conjugates are reshaping precision cancer therapy and discover what it takes to successfully develop, manufacture, and scale these complex biologics.

most read